Neuronetics Inc.
STIM evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for STIM—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · STIM
Neuronetics Inc. (STIM) is a medical technology company focused on developing and commercializing non-invasive neurostimulation therapies for psychiatric disorders, primarily major depressive disorder (MDD).
Key risk: History of operating losses
BioSniper Score
Based on 5 of 6 signals
Market Cap
$156.6M
Cash Runway
8.7 moLead Asset
neurostar advanced therapy system (Approved)
Next Catalyst
—
Financial data as of Mar 31, 2026.
Tracking 1 pipeline candidate · 5 clinical trials for Neuronetics Inc..
Neuronetics Inc. (STIM) is a medical technology company focused on developing and commercializing non-invasive neurostimulation therapies for psychiatric disorders, primarily major depressive disorder (MDD).
- Neuronetics commercializes the NeuroStar Advanced Therapy System for treating major depressive disorder (MDD) [sec].
- As of 2026-03-31, the company reported cash & equivalents of $19.0M, total revenue of $34.5M, and a net loss of -$10.8M [sec].
- The company has a history of operating losses and relies on product sales and potential financing to fund operations [sec · filed 2022-05-12].
- Neuronetics has a significant debt load of $61.3M as of 2026-03-31 [sec].
- The company's forward-looking statements are subject to risks including the impact of the COVID-19 pandemic and its ability to execute business strategies [sec · filed 2021-05-04].
What works
- Neuronetics has a commercialized product, the NeuroStar Advanced Therapy System, generating revenue of $34.5M as of 2026-03-31 [sec].
- The company has a cash position of $19.0M as of 2026-03-31, providing some liquidity for ongoing operations [sec].
What to weigh
- Neuronetics reported a net loss of -$10.8M as of 2026-03-31, indicating ongoing unprofitability [sec].
- The company has a high debt level of $61.3M as of 2026-03-31, which may strain financial flexibility [sec].
- Neuronetics has a history of losses and may need to seek additional financing, which could dilute shareholders [sec · filed 2022-05-12].
- The company faces risks related to the COVID-19 pandemic and its impact on patient access and operations [sec · filed 2021-05-04].
From the filings
Quoted directly from source documents.
Neuronetics has a commercial product generating revenue.
“revenues from sales of its products”
SEC filings · May 12, 2022
The company has a history of losses and may need financing.
“the Company's ability to achieve or sustain profitable operations due to its history of losses”
SEC filings · March 4, 2025
Neuronetics faces risks from the COVID-19 pandemic.
“the ongoing impact of the novel coronavirus, or COVID-19, pandemic on general political and economic uncertainty”
SEC filings · May 4, 2021
The company has significant debt.
“the Company had $35.0 million of borrowings outstanding under its credit facility”
SEC filings · May 12, 2022
Risks & what to watch (4)›
Key risks
- History of operating losses — Neuronetics has a history of losses and may not achieve profitability, as noted in SEC filings [sec · filed 2025-03-04].
- High debt burden — Total debt of $61.3M as of 2026-03-31 could limit financial flexibility and increase risk [sec].
- Dependence on financing — The company may need to raise additional capital, potentially causing dilution [sec · filed 2022-05-12].
- COVID-19 pandemic impact — The pandemic has caused uncertainty in patient access and operations [sec · filed 2021-05-04].
What to watch
- Monitor the company's ability to reduce net losses and achieve profitability, as indicated by future financial reports [sec].
- Watch for updates on debt management and potential refinancing or repayment of the $61.3M debt [sec].
- Track revenue growth from the NeuroStar system and any new product developments or approvals [sec].
- Observe the impact of macroeconomic factors, such as the lingering effects of COVID-19, on patient access and sales [sec · filed 2021-05-04].
Sources: SEC filings · SEC MD&A · Generated August 7, 2026 · How we verify sources →
Run Neuronetics Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Neuronetics Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
8.7 months
D/E 8.17 · 0% dilution
Lead: Approved
1 candidate
No upcoming catalysts tracked
13 buys · 4 sells (180d)
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
96
Total value held
$29.7M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 4,095,950 | $5.9M |
| balyasny asset management l.p. | 2,743,768 | $4.0M |
| blackrock, inc. | 2,318,537 | $3.4M |
| fourworld capital management llc | 1,489,322 | $2.2M |
| masters capital management llc | 1,000,000 | $1.4M |
| geode capital management, llc | 958,989 | $1.4M |
| state street corp | 842,547 | $1.2M |
| ikarian capital, llc | 701,182 | $1.0M |
| wexford capital lp | 700,961 | $1.0M |
| advisorshares investments llc | 617,193 | $895K |
Showing top 10 of 96 institutional holders of Neuronetics Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 22, 2026- % of float
- 30.5%
- Days to cover
- 5.0
- Shares short
- 10,470,096
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
STIM short interestGovernance
Frequently asked questions
What is the AI investment thesis for Neuronetics Inc.?
Neuronetics Inc. (STIM) is a medical technology company focused on developing and commercializing non-invasive neurostimulation therapies for psychiatric disorders, primarily major depressive disorder (MDD).
What is Neuronetics Inc.'s lead drug candidate?
Neuronetics Inc.'s most advanced tracked candidate is neurostar advanced therapy system (Approved) for Major depressive disorder (MDD), obsessive-compulsive disorder (OCD), and anxious depression.
Who is the CEO of Neuronetics Inc.?
Mr. Daniel L. Reuvers is the chief executive officer of Neuronetics Inc. (STIM).
Where is Neuronetics Inc. headquartered?
Neuronetics Inc. (STIM) is headquartered in Malvern, PA, United States.
What therapeutic areas does Neuronetics Inc. focus on?
Neuronetics Inc. develops therapies across Neurology, Psychiatry.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.